Administration of the BCL-2 antagonist, venetoclax, to promote apoptosis of HIV-infected cells and reduce the size of the HIV reservoir: An investigator-initiated phase I/IIb clinical trial in people living with HIV on antiretroviral therapy (The AMBER Study)

Status

Recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518873-32-00

Acronym

AMB-001

Enrollment

Registered

2024-10-23

Start date

2022-10-28

Completion date

Unknown

Last updated

2025-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV-1 disease

Brief summary

Safety defined as treatment-emerging adverse events (AEs) >=grade 3 (as cited as dose limiting toxicities section 4.2) probably or definitely related to study treatment, Safety defined as all other treatment-emerging AEs, graded according to severity and assessed as either not related or possibly, probably or definitely related to study treatment

Interventions

DRUGVenclyxto 100 mg film-coated tablets

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Safety defined as treatment-emerging adverse events (AEs) >=grade 3 (as cited as dose limiting toxicities section 4.2) probably or definitely related to study treatment, Safety defined as all other treatment-emerging AEs, graded according to severity and assessed as either not related or possibly, probably or definitely related to study treatment	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026